Sundar Pichai, in his public debut in Congress, is expected to address privacy, allegations of anti-conservative bias, a censored search tool for China and a scuttled Pentagon contract.
(Image credit: Saul Loeb/AFP/Getty Images)
While much of the farm bill draft mirrors current law, there is a major change coming for farmers: industrial hemp will be legalized. Forestry and food stamps became sticking points.
(Image credit: Bloomberg/Bloomberg via Getty Images)
Users' name, date of birth, email address, work history and other information were exposed for nearly a week in November, Google says.
(Image credit: Google+ /Screenshot by NPR)
Get away from holiday stress and crummy weather with our romance picks for December. We've got great contemporary stories and a charming inversion of that classic Regency trope, the forced engagement.
(Image credit: )
As a partial government shutdown looms, Chuck Schumer and Nancy Pelosi meet the president to discuss border wall funding. Britain seeks changes to Brexit. U.N. climate talks continue in Poland.
Something rare is stirring in Congress. There's growing sentiment to force the president to end U.S. involvement in a war, in this case Yemen, where the U.S. military has been aiding Saudi Arabia.
(Image credit: Jon Gambrell/AP)
With a partial government shutdown on the horizon, President Trump and Democratic leaders are set to discuss border funding and other issues at the White House.
(Image credit: Saul Loeb/AFP/Getty Images)
Fifty-seven percent don't think demanding funding for the wall is worth the gridlock, an NPR/PBS NewsHour/Marist Poll finds. Many do not consider the wall a top priority for the next Congress, either.
(Image credit: Rebecca Blackwell/AP)
Greetings friends, colleagues: my blog BeSpacific has been nominated (4 years in a row) in the category Best Legal Legal Tech Blog.
Please take a minute this week and vote for BeSpacific here – https://www.theexpertinstitute.com/legal-blog/bespacific/ and share this request with your friends and colleagues as well.
There are no prizes or $$ – just “job well done.” I research every day to achieve that goal, and will continue to do so. My readers are the Best!
Many thanks for your support.
Marsden, Gregory, Doing Law School Wrong: Case Teaching and an Integrated Legal Practice Method (November 15, 2018). Available at SSRN: https://ssrn.com/abstract=3284875 or http://dx.doi.org/10.2139/ssrn.3284875
“Since its inception, the Langdellian case method has been used to teach legal analysis and reasoning to generations of U.S. law students. For nearly as long, business school students have used their own version of the case method to learn and practice management decision-making. In law school, a ‘case’ is an appellate court decision, which students must analyze in preparation for Socratic questioning. To business students, a ‘case’ is a narrative problem they must solve, before debating and defending their solutions in a moderated classroom discussion. This paper contrasts the two case methods, first defining the methods themselves, as well as related concepts including Socratic dialogue and problem-based learning. It then asserts that neither the law school nor the business school case method is optimal to prepare students for bar admission and the practice of law. Following a detailed examination of both methods, with particular emphasis on the role of group work, the focus then shifts to a proposed Integrated Legal Practice Method. This proposed method draws on business-school case teaching, in an effort to address the shortcomings of current U.S. legal education by providing students not only with substantive and adjective legal knowledge, but also with the skills necessary for legal practice.”
Pew: “Experts say the rise of artificial intelligence will make most people better off over the next decade, but many have concerns about how advances in AI will affect what it means to be human, to be productive and to exercise free will. Digital life is augmenting human capacities and disrupting eons-old human activities. Code-driven systems have spread to more than half of the world’s inhabitants in ambient information and connectivity, offering previously unimagined opportunities and unprecedented threats. As emerging algorithm-driven artificial intelligence (AI) continues to spread, will people be better off than they are today? Some 979 technology pioneers, innovators, developers, business and policy leaders, researchers and activists answered this question in a canvassing of experts conducted in the summer of 2018. The experts predicted networked artificial intelligence will amplify human effectiveness but also threaten human autonomy, agency and capabilities. They spoke of the wide-ranging possibilities; that computers might match or even exceed human intelligence and capabilities on tasks such as complex decision-making, reasoning and learning, sophisticated analytics and pattern recognition, visual acuity, speech recognition and language translation. They said “smart” systems in communities, in vehicles, in buildings and utilities, on farms and in business processes will save time, money and lives and offer opportunities for individuals to enjoy a more-customized future…”
EveryCRSReport.com: Right to Try: Access to Investigational Drugs, November 27, 2018 – “The Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try (RTT) Act of 2017 became federal law on May 30, 2018. Over the preceding five years, 40 states had enacted related legislation. The goal was to allow individuals with imminently life-threatening diseases or conditions to seek access to investigational drugs without the step of procuring permission from the Food and Drug Administration (FDA). Another goal—held by the Goldwater Institute, which led the initiative toward state bills, and some of the legislative proponents—was focused more on the process: to eliminate government’s role in an individual’s choice. The RTT Act (P.L. 115-176) offers eligible individuals and their physicians a pathway other than FDA’s expanded access procedures to acquiring investigational drugs. It defines an eligible patient as one who (1) has been diagnosed with a life-threatening disease or condition, (2) has exhausted approved treatment options and is unable to participate in a clinical trial involving the eligible investigational drug (as certified by a physician who meets specified criteria), and (3) has given written informed consent regarding the drug to the treating physician. It defines an eligible investigational drug as an investigational drug (1) for which a Phase 1 clinical trial has been completed, (2) that FDA has not approved or licensed for sale in the United States for any use, (3) that is the subject of a new drug application pending FDA decision or is the subject of an active investigational new drug application being studied for safety and effectiveness in a clinical trial, and (4) for which the manufacturer has not discontinued active development or production and which the FDA has not placed on clinical hold…”